SO2: Purchase and housing of African Green Monkeys for use in CEPI High Containment Animal Studies04/01/2022 - 01/31/2025 (PI of Sub-Project / SP)
PI:
Nancy J. Sullivan, ScDCoalition for Epidemic Preparedness Innovations
Efficacy of Wyss-vaccine platforms in hamster model of SARS-CoV-2 infection02/17/2021 - 01/31/2025 (PI)
Hansjorg Wyss Institute for Biologically Inspired Engineering at Harvard
Assays in Support of Filovirus Nonhuman Primate Studies for Advancement of Medical Countermeasures04/14/2022 - 12/31/2024 (Subcontract PI)
Battelle Memorial Institute HHS ASPR BARDA
Model Development and Medical Counter Measures (MCMs) for BSL-4 Agents in NHPs03/16/2022 - 12/01/2024 (PI of Sub-Project / SP)
PI:
Nancy J. Sullivan, ScDNIH/National Institute of Allergy & Infectious Diseases
Discovery and development of antibody therapeutics for SARS-CoV-2 and other high-risk emerging viruses10/30/2020 - 10/29/2024 (Subcontract PI)
President & Fellows of Harvard College on behalf of Harvard Medical School AbbVie
Accelerated development of a SARS-CoV-2 vaccine based on the live VSVG chimeric virus platform02/26/2021 - 09/30/2024 (Subcontract PI)
International AIDS Vaccine Initative Inc. DOD DTRA
Project 3: Integrative Design and Testing09/16/2021 - 08/31/2024 (Subcontract PI)
The Brigham and Women's Hospital, Inc. NIH NIAID1P01AI165072-01
Serologic and Molecular Studies of human anti-hCoV antibody cross-immunity and protective responses among endemic HCoVs and SARS-CoV209/17/2021 - 06/30/2024 (Subcontract PI)
Dana-Farber Cancer Institute NIH NIAID5R01AI161152-03
Discovering Durable Pan-Coronavirus Immunity09/16/2021 - 06/30/2024 (Subcontract PI)
The Brigham and Women's Hospital, Inc. NIH NIAID1P01AI165072-03
Efficacy testing of a Marburg Virus Monoclonal Antibody Medical Countermeasure01/16/2023 - 04/30/2024 (Subcontract PI)
Mapp Biopharmaceutical, Inc. HHS ASPR BARDA
Neutralization of SARS-CoV-2 with rationally designed antibody-based therapeutics02/15/2022 - 01/31/2024 (PI)
Cidara Therapeutics, Inc.
Pilot efficacy testing of a Sudan Virus Monoclonal Antibody Medical Countermeasure07/14/2022 - 08/09/2023 (Subcontract PI)
Mapp Biopharmaceutical, Inc. HHS ASPR BARDA
Novel Inhaled Nitric Oxide Therapy for Pulmonary Treatments (COVID-19)01/24/2023 - 07/31/2023 (Subcontract PI)
MedChem Partners National Science FdnIIP-2040043
Determine the efficacy of Codiak's exosome-based vaccine delivery platform in rodent models of coronavirus infection12/01/2022 - 06/30/2023 (Subcontract PI)
CODIAK BIOSCIENCES INC. Coa Epi Prep Inno
Inactivation of SARS CoV-2 Using light at various wavelengths08/20/2020 - 06/30/2023 (PI)
EP Consultants, Inc.
Rationally Designed Pan-Ebolavirus Vaccine12/01/2019 - 05/31/2023 (Subcontract PI)
Integrated BioTherapeutics, Inc. NIH NIAID5R01AI132204-05
Model development/ refinement study Ebola virus Makona intranasal challenge04/16/2021 - 04/16/2023 (PI)
Janssen Vaccines & Prevention B.V.
Determine the neutralization potency of IMM20253 +/- a series of antibodies against the clinical isolate of the omicron variant as compared to the WA1/2020 D614G reference SARS-CoV-2 strain01/15/2022 - 03/31/2023 (PI)
Immunome, Inc.
In vivo studies of SARS-CoV-2 variants10/15/2021 - 03/31/2023 (PI)
President & Fellows of Harvard College on behalf of Harvard Medical School
Inactivation of SARS CoV-2 and other viruses Using Signify lighting technologies11/01/2020 - 01/31/2023 (PI)
Signify North America Corporation
MIT Funded Project of SARS-CoV-2 Infection of Vaccinated Mice01/01/2022 - 12/31/2022 (Subcontract PI)
Massachusetts Institute of Technology Microsoft
SO1: Infrastructure and Installation of Caging to support CEPI High Containment Animal Studies04/01/2022 - 11/30/2022 (PI)
Coalition for Epidemic Preparedness Innovations
Moderna SARS-CoV-2 Hamster challenge study (150)03/20/2021 - 09/30/2022 (PI)
Moderna Therapeutics
Efficacy of modified ACE-2 in a hamster model of SARS-CoV-2 infection09/01/2020 - 07/31/2022 (Subcontract PI)
The Children's Hospital Corporation Emerg Vnt@George Mas
Stimulating host innate immunity to protect against Ebola virus07/02/2021 - 06/30/2022 (Subcontract PI)
Bolder Biotechnology Inc. NIH NIAID1R43AI157684-01A1
MIT fiunded project of SARS-CoV-2 infection of vaccinated mice09/01/2021 - 12/31/2021 (PI)
Massachusetts Institute of Technology
Efficacy of UMASS Test Article in hamster model of SARS-CoV-2 disease05/01/2021 - 12/31/2021 (PI)
University of Massachusetts, Worcester
Efficacy of Immunome antibodies against SARS CoV-2 in hamsters09/22/2020 - 12/31/2021 (Subcontract PI)
Immunome, Inc. DOD Army
Inactivation of SARS CoV-2 Using Supercritical CO208/01/2020 - 09/30/2021 (PI)
Spectra Systems Corporation
Characterization of the Disease Course in Rhesus Macaques Infected with Ebola Virus11/13/2018 - 09/16/2021 (Subcontract PI)
MRI Global HHS ASPR BARDA
Efficacy of nanodiscs in a hamster model of SARS-CoV-2 infection03/01/2021 - 08/31/2021 (PI)
The Brigham and Women's Hospital, Inc.
Neutralization of SARS-CoV-2 with rationally designed antibody-based therapeutics08/21/2020 - 08/20/2021 (PI)
Cidara Therapeutics, Inc.
Efficacy testing of antiviral drug in a hamster model of SARS CoV-2 infection08/01/2020 - 08/01/2021 (PI)
Boston Pharmaceuticals, Inc.
Development of SARS-CoV2 neutralizing antibody02/01/2021 - 07/31/2021 (PI)
Richard King Mellon Foundation
Efficacy of RNA-based therapeutic in an NHP model of SARS-CoV-2 infection09/01/2020 - 06/30/2021 (PI)
University of Massachusetts Medical School
Inactivation of SARS CoV-2 Using UV-C06/01/2020 - 06/30/2021 (PI)
Crystal IS, Inc.
Evaluation of the efficacy of convalescent anti-Ebola virus intravenous immune globulin in the treatment of Ebola virus disease in a lethal mouse model05/01/2020 - 06/30/2021 (PI)
Grifols Inc.
STTR Phase II: Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease11/01/2019 - 06/30/2021 (Subcontract PI)
Integrated BioTherapeutics, Inc. NIH NIAID5R42AI122403-03
RESTRICTED: STTR Phase II: Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease11/01/2019 - 06/30/2021 (Subcontract PI)
Integrated BioTherapeutics, Inc. NIH NIAID5R42AI122403-03
Efficacy of Immunome antibodies against SARS CoV-2 in hamsters09/22/2020 - 06/01/2021 (PI)
Immunome, Inc.
Evaluation of protective effect against SARS-CoV-2 challenge of AAVCOVID19-1 (AC1) and AAVCOVID19-3 (AC3) vaccines07/01/2020 - 03/30/2021 (Subcontract PI)
Massachusetts Eye and Ear Infirmary & Physician Staff, Inc. Albamunity, Inc.
Inactivation of SARS CoV-2 Using Rapiscan Trace Detection System08/25/2020 - 01/31/2021 (PI)
Rapiscan Systems, Inc.
Restricted: Natural History of Rhesus Macaques Infected with Sudan Ebolavirus Disease03/22/2019 - 10/31/2020 (Subcontract PI)
Texas Biomedical Research Institute HHS ASPR BARDA
RESTRICTED: Natural History of Rhesus Macaques Infected with Marburg Virus03/22/2019 - 10/31/2020 (Subcontract PI)
Texas Biomedical Research Institute HHS ASPR BARDA
Inactivation of SARS CoV-2 Using UV-C06/01/2020 - 07/15/2020 (PI)
Signify North America Corporation
Natural History of Rhesus Macaques Infected with Marburg Virus03/22/2019 - 10/31/2019 (Subcontract PI)
Texas Biomedical Research Institute HHS ASPR BARDA
Natural History of Rhesus Macaques Infected with Sudan Ebolavirus Disease03/22/2019 - 10/31/2019 (Subcontract PI)
Texas Biomedical Research Institute HHS ASPR BARDA